AstraZeneca Announced Sunday, Phase 3 CLARITY-Gastric01 Trial Met Primary Overall Survival Endpoint; Sone-Ve Reduced Risk Of Death By 53% In Later-Line CLDN18.2-Positive Advanced Gastric Cancer

뉴스 본문을 불러오고 있어요.

AstraZeneca Announced Sunday, Phase 3 CLARITY-Gastric01 Trial Met Primary Overall Survival Endpoint; Sone-Ve Reduced Risk Of Death By 53% In Later-Line CLDN18.2-Positive Advanced Gastric Cancer | 웨이프 WAPE

AstraZeneca Announced Sunday, Phase 3 CLARITY-Gastric01 Trial Met Primary Overall Survival Endpoint; Sone-Ve Reduced Risk Of Death By 53% In Later-Line CLDN18.2-Positive Advanced Gastric Cancer

기사 요약

관련 종목

댓글 —